

**THE ANNUAL REPORT FOR 2008 NOW AVAILABLE ON
KARO BIO'S WEB SITE**

As of today, Karo Bio's annual report for 2008 is available on the company's web site, www.karobio.com

The printed version of the annual report will be distributed to shareholders and others specifically subscribing to the printed version. It can also be ordered from Karo Bio by mail to Karo Bio AB, att. Eva Kruse, Novum, 141 57 Huddinge, Sweden, by fax to +46 8 774 52 80, or by e-mail to investor@karobio.com.

For further information, please contact:

Per Otteskog, *Senior Vice President Investor Relations*

Phone: +46 8 608 60 18

Erika Johnson, *Chief Financial Officer*

Phone: +46 8 608 60 52

About Karo Bio

Karo Bio is a drug discovery and development company specializing in targeting nuclear receptors for the development of novel pharmaceuticals.

The company has a project portfolio with innovative molecules that primarily target cardiovascular, metabolic and inflammatory diseases as well as women's health. In these areas, there are significant market opportunities and a need for pharmaceuticals with new mechanisms of action. Karo Bio develops compounds aimed at treatment of broad patient populations up to clinical proof of concept before out-licensing. In therapeutic niche areas, Karo Bio has capacity to bring selected compounds into late stage clinical development and, potentially, to the market. In addition to the proprietary projects, Karo Bio has three strategic collaborations with international pharmaceutical companies for development of innovative therapies for the treatment of common diseases.

Karo Bio is listed on NASDAQ OMX Stockholm since 1998 (Reuters: KARO.ST).

This press release is also available online at: www.karobio.com and www.newsroom.cision.com